Neuraxis, Inc. (NRXS) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Neuraxis, Inc. on November 25, 2024, covering events occurring on November 19, 2024. The Company is incorporated in Delaware and trades on the NYSE American under the symbol NRXS. It is classified as an emerging growth company.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, or debt levels. The only financial data disclosed relates to a specific capital transaction:
- Capital Raised: Approximately $5 million aggregate purchase price.
- Instrument: 2,100,840 shares of Series B Convertible Preferred Stock.
- Investors: Three related investors, including Dr. Gil Aharon.
Material Changes
The primary material change reported is the appointment of a new director to the Board of Directors. This appointment is a direct result of a securities purchase agreement (SPA) entered into on November 9, 2024, and closed on November 19, 2024.
- Board Appointment: Dr. Gil Aharon was appointed to the Board, effective January 1, 2025.
- Role: Dr. Aharon serves as the designee of the Investors. He is the co-founder of Rosalind Advisors, Inc., which advised one of the investors.
- Personal Investment: Dr. Aharon purchased 105,042 shares of Series B Preferred Stock for approximately $250,000.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard disclosures regarding the transaction. Regarding the new director:
- Committee Assignments: Dr. Aharon has not yet been appointed to any Board committees.
- Compensation: Director compensation for Dr. Aharon has not yet been determined.
- Related Party Transactions: Other than the Series B purchase, Dr. Aharon has no other material interests in transactions requiring disclosure.
Investor Verification Checklist
- Verify the terms of the Series B Convertible Preferred Stock, including conversion rates and liquidation preferences, which are not detailed in this 8-K.
- Confirm the final compensation package for Dr. Aharon once determined by the Board.
- Review the full Securities Purchase Agreements (SPAs) to understand the rights and obligations of the three related investors.
- Monitor future filings for the effective date of Dr. Aharon's board service (January 1, 2025) and any subsequent committee assignments.